Skip to main content
Premium Trial:

Request an Annual Quote

Sequenom Posts Slight Rise in Q4 Revenues, Decrease in Net Losses

NEW YORK, Feb. 10 (GenomeWeb News) - Sequenom today reported an uptick in revenues for the fourth quarter ended Dec. 31, 2003, accompanied by narrowed losses and decreased R&D spending.

Sequenom's consolidated revenues for the quarter were $8.0 million, up slightly from $7.7 million in the year-ago period. The company's Genetic Systems business unit posted revenues of $7.7 million for the quarter, up from $7.2 million for the fourth quarter of 2002. Revenues for the company's pharmaceuticals business unit were down year-over-year, to $300,000 from $500,000 in the fourth quarter of 2002. Sequenom said these revenues resulted primarily from genetic services.

The company reported a 78 percent decrease in its net loss for the quarter, to $10.0 million, or $0.25 per share, from $45.8 million, or $1.16 per share, in the fourth quarter of 2002.

Sequenom's R&D expenses were $7.0 million for the fourth quarter, down from $8.0 million in the prior year.

On Dec. 31, 2003, Sequenom held cash, cash equivalents, short-term investments, and restricted cash totaling $67.5 million, compared to $102.6 million at the end of 2002.

The Scan

Omicron's Emergence

The World Health Organization has called Omicron a SARS-CoV-2 "variant of concern," the Los Angeles Times writes.

Not as Much

Merck's pill to treat COVID-19 reduces the risk of hospitalization and death among COVID-19 patients by less than previously reported, the New York Times says.

Bats That Hang Together

Discover magazine writes that researchers have found a social microbiome among vampire bats.

PLOS Papers on CEWAS, Simian Varicella Virus Transcriptome, Dermatomyositis Markers

In PLOS this week: multi-omic approach to home in on genetic risk variants, transcriptomic analysis of the simian varicella virus, and more.